HER2、COX-2及GST-π在胃癌中的表达及意义

Expressions and significance of HER2,COX-2 and GST-π in human gastric carcinoma

目的:探讨胃癌组织中人表皮生长因子受体-2(HER2)、环氧合酶-2(COX-2)和胎盘型谷胱甘肽-S-转移酶-π(GST-π)的表达及与临床病理特征的关系。方法:应用免疫组化Envision二步法,检测70例胃癌组织和12例正常胃组织中HER2、COX-2及GST-π的表达情况,并结合其临床病理特点进行分析。结果:HER2在胃癌中的阳性表达率为27.1%,在正常胃组织中无表达;COX-2在胃癌中的阳性率为67.1%,在正常胃组织中的阳性率为16.7%;GST-π在胃癌中的阳性表达率为58.6%,在正常胃组织中的阳性率为25.0%,三种蛋白分别在胃癌及正常组织中的表达差异具有统计学意义(P<0.05,P<0.01,P<0.05);HER2、COX-2及GST-π在胃癌组织中的阳性表达与肿瘤分化程度、侵袭深度、有无淋巴结转移及TNM分期有关(P<0.05),而与患者的性别及年龄、肿瘤部位和大小无关(P>0.05)。HER2、COX-2及GST-π三者之间在胃癌组织中的表达均呈正相关(P<0.05)。结论:HER2、COX-2及GST-π参与胃癌的生长、侵袭和转移过程。联合检测有助于胃癌患者靶向药物联合化疗药物的初筛及对胃癌患者的预后评价。

Objective：To investigate the expressions of HER2, COX -2 and GST-π in human gastric carcinoma and to study the relationship among them and the clinicopathological factors of gastric carcinoma. Methods： The Envision immunohistochemical stain method was used to detect HER2, COX - 2 and GST - π protein expressions in 70 samples of gastric carcinoma tissues and 12 cases of normal gastric mucosa. And clinical data were analyzed retrospectively. Results：Positive rate of HER2 was 27.1%, and none of normal gastric mucosa was stained. The positive rate of COX - 2 protein was 67.1% in gastric carcinoma tissues and 16.7% in normal gastric mucosa. The positive rate of GST - π was 58.6% in gastric carcinoma tissues and 25.0% in normal gastric mucosa. There existed significant difference between the two groups （ P 〈 0.05, P 〈 0.01, P 〈 0. 05 ）. The positive expression rates of HER2, COX - 2 and GST - π protein in gastric carcinoma tissues were closely related to the differentiation of the carcinoma, invasion depth,lymphatic metastasis and TNM （ P 〈 0.05 ）, but not to the patient＇s sex, age, tumor site and size （ P 〉 0.05 ）. There was a stable positive correlation among HER2, COX - 2 and GST - π expressions in gastric carcinoma tissues. Conclusion： HER2, COX - 2 and GST - π participate the development, invasion and metastasis process of gastric carcinoma. Joint detection of them can be looked as a primary detection for guiding the molecular targeting therapy and chemotherapy of gastric carcinoma, and judging the prognosis of gastric carcinoma and providing basis for gene detection.